Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.22 USD | -0.10% | +12.79% | +134.74% |
May. 23 | Dyne Therapeutics Insider Sold Shares Worth $1,002,751, According to a Recent SEC Filing | MT |
May. 22 | Dyne Therapeutics Prices $325.5 Million Common Stock Offering | MT |
Business Summary
Number of employees: 143
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jason Rhodes
FOU | Founder | 54 | 17-11-30 |
Rick Scalzo
DFI | Director of Finance/CFO | 38 | 19-11-30 |
John Najim
CTO | Chief Tech/Sci/R&D Officer | 48 | 19-07-31 |
Chief Tech/Sci/R&D Officer | 63 | 20-01-26 | |
Chief Tech/Sci/R&D Officer | 61 | 19-06-27 | |
Wildon Farwell
CTO | Chief Tech/Sci/R&D Officer | 49 | 21-03-03 |
Ashish Dugar
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-07 |
Susanna High
COO | Chief Operating Officer | 56 | 20-06-30 |
Amy Reilly
IRC | Investor Relations Contact | 51 | 20-06-30 |
Daniel Wilson
LAW | General Counsel | 53 | 20-05-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Edward Hurwitz
BRD | Director/Board Member | 60 | 18-10-31 |
David Lubner
BRD | Director/Board Member | 60 | 20-02-29 |
Dirk Kersten
BRD | Director/Board Member | 49 | 18-10-31 |
Jason Rhodes
FOU | Founder | 54 | 17-11-30 |
Carlo Incerti
BRD | Director/Board Member | 65 | 22-03-01 |
Chief Tech/Sci/R&D Officer | 61 | 19-06-27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 87,382,638 | 86,913,706 ( 99.46 %) | 0 | 99.46 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+134.74% | 3.05B | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.98% | 40.65B | |
-10.87% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- DYN Stock
- Company Dyne Therapeutics, Inc.